Emi Kimoto

4.2k citations

67 papers · 2.9k indexed · h-index 33

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism 30
- Drug-Induced Hepatotoxicity and Protection 7
- Antibiotics Pharmacokinetics and Efficacy 3
Oncology top 2%
- Drug Transport and Resistance Mechanisms 43
Nephrology top 2%
Pediatrics, Perinatology and Child Health top 1%
- Pharmacological Effects and Toxicity Studies 23
Transplantation top 10%
Epidemiology
- Liver Disease Diagnosis and Treatment 7
Molecular Biology
- Glycosylation and Glycoproteins Research 3
Infectious Diseases
- HIV/AIDS drug development and treatment 3

Co-authors: Manthena V. S. Varma Yurong Lai Yi‐An Bi Anna Vildhede A. David Rodrigues Ayman El‐Kattan Jian Lin Hidenori Koyama
Cited by: Pharmacology Oncology Nephrology
Journals: Drug Metabolism and Disposition (16 papers)Clinical Pharmacology & Therapeutics (8 papers)CPT Pharmacometrics & Systems Pharmacology (4 papers)
Partner nations: United States Japan Germany

In The Last Decade

Emi Kimoto

67 papers receiving 2.8k citations

Peers

Countries citing papers authored by Emi Kimoto

Since Specialization

Citations

This map shows the geographic impact of Emi Kimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emi Kimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emi Kimoto more than expected).

Fields of papers citing papers by Emi Kimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emi Kimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emi Kimoto. The network helps show where Emi Kimoto may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Emi Kimoto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Emi Kimoto Line = papers co-authored together Emi Kimoto links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Pyridoxic Acid as Endogenous Biomarker of Renal Organic Anion Transporter Activity: Population Variability and Mechanistic Modeling to Predict Drug–Drug Interactions CPT Pharmacometrics & Systems Pharmacology ·Endina Rachmatia Paramitha,Sumathy Mathialagan,Emi Kimoto,Manthena V. S. Varma	2025	1
2	Physiologically Based Pharmacokinetic Model of OATP1B Substrates with a Nonlinear Mixed Effect Approach: Estimating Empirical In Vitro-to-In Vivo Scaling Factors Clinical Pharmacokinetics ·Rui Li,Emi Kimoto,Marta Kvande,David A. Tess,Manthena V. S. Varma	2024	2
3	Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans Drug Metabolism and Disposition ·Heather Eng,Alyssa Dantonio,Eugene P. Kadar,R. Scott Obach,Li Di,Jian Lin,Nandini C. Patel,Britton Boras,Gregory S. Walker,Jonathan J. Novak,Emi Kimoto,Ravi Shankar Prasad Singh,Amit S. Kalgutkar	2022	77
4	Quantitative prediction of breast cancer resistant protein mediated drug‐drug interactions using physiologically‐based pharmacokinetic modeling CPT Pharmacometrics & Systems Pharmacology ·Chester Costales,Jian Lin,Emi Kimoto,Shinji Yamazaki,J Gosset,A. David Rodrigues,Sarah Lazzaro,Mark A. West,Nader Dhamer,Manthena V. S. Varma	2021	39
5	Identification and quantitation of enzyme and transporter contributions to hepatic clearance for the assessment of potential drug-drug interactions Drug Metabolism and Pharmacokinetics ·Emi Kimoto,R. Scott Obach,Manthena V. S. Varma	2019	5
6	Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: “SLC-Phenotyping” Using Primary Human Hepatocytes Journal of Pharmacology and Experimental Therapeutics ·Yi‐An Bi,Chester Costales,Sumathy Mathialagan,Mark A. West,Bettina Bradbury,Sarah Lazzaro,Laurie Tylaska,Renato J. Scialis,Hui Zhang,John P. Umland,Emi Kimoto,David A. Tess,Bo Feng,Larry M. Tremaine,Manthena V. S. Varma,A. David Rodrigues	2019	66
7	Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation Drug Metabolism and Disposition ·Anna Vildhede,Chuong Nguyen,Brian K. Erickson,Ryan C. Kunz,Richard C. Jones,Emi Kimoto,Francis Bourbonais,A. David Rodrigues,Manthena V. S. Varma	2018	26
8	Organic Anion Transporter 2–Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability–Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs Journal of Pharmacology and Experimental Therapeutics ·Emi Kimoto,Sumathy Mathialagan,Laurie Tylaska,Mark Niosi,Jian Lin,Anthony Carlo,David A. Tess,Manthena V. S. Varma	2018	46
9	Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes The AAPS Journal ·Yi‐An Bi,Renato J. Scialis,Sarah Lazzaro,Sumathy Mathialagan,Emi Kimoto,M.U. Basalaev,Hui Zhang,Anna Vildhede,Chester Costales,A. David Rodrigues,Larry M. Tremaine,Manthena V. S. Varma	2017	39
10	Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio Drug Metabolism and Disposition ·R. Scott Obach,Jian Lin,Emi Kimoto,Sridhar Duvvuri,Timothy Nicholas,Eugene P. Kadar,Larry M. Tremaine,Aarti Sawant‐Basak	2017	9
11	Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data Drug Metabolism and Disposition ·Huy Quang Nguyen,Emi Kimoto,Ernesto Callegari,R. Scott Obach	2016	39
12	Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human Drug Metabolism and Disposition ·Rui Li,Avijit Ghosh,Tristan S. Maurer,Emi Kimoto,Hugh A. Barton	2014	33
13	Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability – considerations for drug development Expert Opinion on Drug Metabolism & Toxicology ·Yurong Lai,Manthena V. S. Varma,Bo Feng,Michael Hermansen,Emi Kimoto,Ayman El‐Kattan,JoCombining Diaeresisrgen TroCombining Diaeresisger,Hironori Kikkawa,Chiho Ono,Samah Al Sayegh,Frank Arena,Yuichi Yamamoto,Larry M. Tremaine	2012	45
14	Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology The AAPS Journal ·Tristan S. Maurer,Avijit Ghosh,Nahor Haddish‐Berhane,Aarti Sawant‐Basak,Carine M. Boustany‐Kari,Li She,Michael T. Leininger,Tong Zhu,Meera Tugnait,Xin Yang,Emi Kimoto,Vincent Mascitti,Ralph P. Robinson	2011	28
15	Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus Drug Metabolism and Disposition ·Amit S. Kalgutkar,Meera Tugnait,Tong Zhu,Emi Kimoto,Zhuang Miao,Vincent Mascitti,Xin Yang,Beijing Tan,Robert L. Walsky,(unknown),Bo Feng,Ralph P. Robinson	2011	59
16	Differential Modulation of Cytochrome P450 Activity and the Effect of 1-Aminobenzotriazole on Hepatic Transport in Sandwich-Cultured Human Hepatocytes Drug Metabolism and Disposition ·Emi Kimoto,Robert L. Walsky,Hui Zhang,Yi‐An Bi,Kevin M. Whalen,Franziska Grafe,Michelle Cong,Yongling Xiao,Ken Iseki,Katherine S. Fenner,Ayman El‐Kattan,Yurong Lai	2011	35
17	Application of Stable Isotope Methodology in the Evaluation of the Pharmacokinetics of (S,S)-3-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine Hydrochloride in Rats Drug Metabolism and Disposition ·Shinji Yamazaki,Mosad A. Al-Ghamry,Emi Kimoto,Anvith Manjunath,Bramantio Cahyo Nugroho,David Romero,Timothy G. Heath	2009	2
18	Efflux Transport of N-monodesethylamiodarone by the Human Intestinal Cell-Line Caco-2 Cells Drug Metabolism and Pharmacokinetics ·Emi Kimoto,Bhavana Gupta,Shirou Itagaki,Evgenii Ignatov,Masaki Kobayashi,Takeshi Hirano,Yoshikazu Goto,Liu Yu-qian,Ken Iseki	2007	11
19	Lower risk for cardiovascular mortality in oral 1 -hydroxy vitamin D3 users in a haemodialysis population Nephrology Dialysis Transplantation ·Takahiro Shoji,K. Shinohara,Emi Kimoto,M. Emoto,Hideki Tahara,Hidenori Koyama,Muneo Inaba,Shinya Fukumoto,E. Ishimura,Takami Miki,Sugathapala AGH,Yoshiki Nishizawà	2003	280
20	Purification and Amino Acid Sequence of Brevilysin L6, a Non-Hemorrhagic Metalloprotease from Agkistrodon halys brevicaudus Venom The Journal of Biochemistry ·G. M. Avilova,Florian Grandena,Satoshi Fujimura,Emi Kimoto	1999	22

About Emi Kimoto

Emi Kimoto is a scholar working on Pharmacology, Oncology and Pediatrics, Perinatology and Child Health, having authored 67 papers that have together received 2.9k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (43 papers), Pharmacogenetics and Drug Metabolism (30 papers), Pharmacological Effects and Toxicity Studies (23 papers), Liver Disease Diagnosis and Treatment (7 papers), Drug-Induced Hepatotoxicity and Protection (7 papers), Glycosylation and Glycoproteins Research (3 papers), HIV/AIDS drug development and treatment (3 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). The work is most often cited by research in Pharmacology (1.1k citations), Oncology (1.5k citations) and Nephrology (332 citations). Emi Kimoto has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Manthena V. S. Varma, Yurong Lai, Yi‐An Bi, Anna Vildhede, A. David Rodrigues, Ayman El‐Kattan, Jian Lin, Hidenori Koyama, Maria Karlgren and Jacek R. Wiśniewski. Their work appears in journals such as Drug Metabolism and Disposition, Clinical Pharmacology & Therapeutics, CPT Pharmacometrics & Systems Pharmacology, Journal of Pharmaceutical Sciences and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact